Now showing items 1-15 of 15

    • Activation of the PD-1 Pathway Contributes to Immune Escape in EGFR-Driven Lung Tumors 

      Akbay, E; Koyama, S.; Carretero, J.; Altabef, A.; Tchaicha, J. H.; Christensen, Camilla Laulund; Mikse, O. R.; Cherniack, Andrew David; Beauchamp, Ellen Monica; Pugh, T; Wilkerson, M. D.; Fecci, P; Butaney, M.; Reibel, J. B.; Soucheray, M.; Cohoon, T. J.; Janne, Pasi Antero; Meyerson, Matthew Langer; Hayes, D. N.; Shapiro, Geoffrey Ira; Shimamura, T; Sholl, Lynette Marie; Rodig, Scott J.; Freeman, Gordon James; Hammerman, Peter Seth; Dranoff, G; Wong, Kwok-Kin (American Association for Cancer Research (AACR), 2013)
      The success in lung cancer therapy with Programmed Death (PD)-1 blockade suggests that immune escape mechanisms contribute to lung tumor pathogenesis. We identified a correlation between Epidermal Growth Factor Receptor ...
    • Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints 

      Koyama, Shohei; Akbay, Esra A.; Li, Yvonne Y.; Herter-Sprie, Grit S.; Buczkowski, Kevin A.; Richards, William G.; Gandhi, Leena; Redig, Amanda J.; Rodig, Scott J.; Asahina, Hajime; Jones, Robert E.; Kulkarni, Meghana M.; Kuraguchi, Mari; Palakurthi, Sangeetha; Fecci, Peter E.; Johnson, Bruce E.; Janne, Pasi A.; Engelman, Jeffrey A.; Gangadharan, Sidharta P.; Costa, Daniel B.; Freeman, Gordon J.; Bueno, Raphael; Hodi, F. Stephen; Dranoff, Glenn; Wong, Kwok-Kin; Hammerman, Peter S. (Nature Publishing Group, 2016)
      Despite compelling antitumour activity of antibodies targeting the programmed death 1 (PD-1): programmed death ligand 1 (PD-L1) immune checkpoint in lung cancer, resistance to these therapies has increasingly been observed. ...
    • Chemotherapy for locally advanced and metastatic pulmonary carcinoid tumors 

      Chong, Curtis Robert; Wirth, Lori Julin; Nishino, Mizuki; Chen, Aileen Betty; Sholl, Lynette Marie; Kulke, Matthew H; McNamee, Ciaran; Janne, Pasi Antero; Johnson, Bruce Evan (Elsevier BV, 2014)
      Objectives The optimal management of locally advanced and metastatic pulmonary carcinoid tumors remains to be determined. Materials and methods A retrospective review was conducted on patients with typical and ...
    • Clinical, Pathologic, and Biologic Features Associated with BRAF Mutations in Non-Small Cell Lung Cancer 

      Cardarella, S.; Ogino, Atsuko; Nishino, Michiya; Butaney, M.; Shen, Jeanne; Lydon, C.; Yeap, Beow Yong; Sholl, Lynette Marie; Johnson, Bruce Evan; Janne, Pasi Antero (American Association for Cancer Research (AACR), 2013)
      Purpose BRAF mutations are found in a subset of non-small cell lung cancers (NSCLCs). We examined the clinical characteristics and treatment outcomes of patients with NSCLC harboring BRAF mutations. Experimental ...
    • EGFRMutation Is a Better Predictor of Response to Tyrosine Kinase Inhibitors in Non–Small Cell Lung Carcinoma Than FISH, CISH, and Immunohistochemistry 

      Sholl, Lynette Marie; Xiao, Yun; Joshi, Victoria; Yeap, Beow Yong; Cioffredi, Leigh-Anne; Jackman, David M; Lee, Charles; Janne, Pasi Antero; Lindeman, Neal I. (Oxford University Press (OUP), 2010)
      About 10% of patients with non–small cell lung carcinoma (NSCLC) respond to epidermal growth factor receptor (EGFR)-targeted tyrosine kinase inhibitors (TKIs). More than 75% of “responders” have activating mutations in ...
    • Impact of oncogenic driver mutations on feedback between the PI3K and MEK pathways in cancer cells 

      Yuen, Hiu-Fung; Abramczyk, Olga; Montgomery, Grant; Chan, Ka-Kui; Huang, Yu-Han; Sasazuki, Takehiko; Shirasawa, Senji; Gopesh, Srivastava; Chan, Kwok-Wah; Fennell, Dean; El-Tanani, Mohamed; Janne, Pasi Antero; Murray, James T. (Portland Press Ltd., 2012)
      Inhibition of the PI3K (phosphoinositide 3-kinase)/Akt/mTORC1 (mammalian target of rapamycin complex 1) and Ras/MEK [MAPK (mitogen-activated protein kinase)/ERK (extracellular-signal-regulated kinase) kinase]/ERK pathways ...
    • The impact of tumor profiling approaches and genomic data strategies for cancer precision medicine 

      Garofalo, Andrea; Sholl, Lynette; Reardon, Brendan; Taylor-Weiner, Amaro; Amin-Mansour, Ali; Miao, Diana; Liu, David; Oliver, Nelly; MacConaill, Laura; Ducar, Matthew; Rojas-Rudilla, Vanesa; Giannakis, Marios; Ghazani, Arezou; Gray, Stacy; Janne, Pasi; Garber, Judy; Joffe, Steve; Lindeman, Neal; Wagle, Nikhil; Garraway, Levi A.; Van Allen, Eliezer M. (BioMed Central, 2016)
      Background: The diversity of clinical tumor profiling approaches (small panels to whole exomes with matched or unmatched germline analysis) may engender uncertainty about their benefits and liabilities, particularly in ...
    • Long-term Benefit of PD-L1 Blockade in Lung Cancer Associated with JAK3 Activation 

      Van Allen, Eliezer Mendel; Golay, H. G.; Liu, Yan; Koyama, S.; Wong, Kwok-Kin; Taylor-Weiner, Amaro; Giannakis, Marios; Harden, M.; Rojas-Rudilla, V.; Chevalier, A.; Thai, T.; Lydon, C.; Mach, S.; Wong, J. A.; Rabin, A. R.; Helmkamp, J.; Sholl, Lynette Marie; Carter, Scott Lambert; Oxnard, Geoffrey Raymond; Janne, Pasi Antero; Getz, Gad A; Lindeman, Neal I.; Hammerman, Peter Seth; Garraway, Levi Alexander; Hodi, Frank Stephen; Rodig, Scott J.; Dranoff, G; Wong, Kwok-Kin; Barbie, David Allen (American Association for Cancer Research (AACR), 2015)
      PD-1 immune checkpoint blockade occasionally results in durable clinical responses in advanced metastatic cancers. However, mechanism-based predictors of response to this immunotherapy remain incompletely characterized. ...
    • Lung Adenocarcinoma with EGFR Amplification Has Distinct Clinicopathologic and Molecular Features in Never-Smokers 

      Sholl, Lynette Marie; Yeap, Beow Yong; Iafrate, Anthony John; Holmes-Tisch, A. J.; Chou, Y.-P.; Wu, Ming-Tsang; Goan, Y.-G.; Su, Li; Benedettini, E.; Yu, J.; Loda, Massimo; Janne, Pasi Antero; Christiani, David Christopher; Chirieac, Lucian Radu (American Association for Cancer Research (AACR), 2009)
      In a subset of lung adenocarcinomas the epidermal growth factor receptor (EGFR) is activated by kinase domain mutations and/or gene amplification, but the interaction between the two types of abnormalities is complex and ...
    • MET Exon 14 Mutations in Non–Small-Cell Lung Cancer Are Associated With Advanced Age and Stage-Dependent MET Genomic Amplification and c-Met Overexpression 

      Awad, Mark Magdi; Oxnard, Geoffrey Raymond; Jackman, David M; Savukoski, Daniel O.; Hall, Dimity; Shivdasani, Priyanka; Heng, Jennifer C.; Dahlberg, Suzanne Eleanor; Janne, Pasi Antero; Verma, Suman; Christensen, James; Hammerman, Peter Seth; Sholl, Lynette Marie (American Society of Clinical Oncology (ASCO), 2016)
      Purpose Non–small-cell lung cancers (NSCLCs) harboring mutations in MET exon 14 and its flanking introns may respond to c-Met inhibitors. We sought to describe the clinical, pathologic, and genomic characteristics of ...
    • Oncologists' and Cancer Patients' Views on Whole-Exome Sequencing and Incidental Findings: Results from The CanSeq Study 

      Gray, Stacy W.; Park, Elyse R.; Najita, Julie; Martins, Yolanda; Traeger, Lara; Bair, Elizabeth; Gagne, Joshua; Garber, Judy; Jänne, Pasi A.; Lindeman, Neal; Lowenstein, Carol; Oliver, Nelly; Sholl, Lynette; Van Allen, Eliezer M.; Wagle, Nikhil; Wood, Sam; Garraway, Levi; Joffe, Steven (2016)
      Purpose While targeted sequencing improves outcomes for many cancer patients, how somatic and germline whole-exome sequencing (WES) will integrate into care remains uncertain. Methods: We conducted surveys and interviews, ...
    • RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer 

      Niederst, Matthew J.; Sequist, Lecia V.; Poirier, John T.; Mermel, Craig H.; Lockerman, Elizabeth L.; Garcia, Angel R.; Katayama, Ryohei; Costa, Carlotta; Ross, Kenneth N.; Moran, Teresa; Howe, Emily; Fulton, Linnea E.; Mulvey, Hillary E.; Bernardo, Lindsay A.; Mohamoud, Farhiya; Miyoshi, Norikatsu; VanderLaan, Paul A.; Costa, Daniel B.; Jänne, Pasi A.; Borger, Darrell R.; Ramaswamy, Sridhar; Shioda, Toshi; Iafrate, Anthony J.; Getz, Gad; Rudin, Charles M.; Mino-Kenudson, Mari; Engelman, Jeffrey A. (Nature Pub. Group, 2015)
      Tyrosine kinase inhibitors are effective treatments for non-small-cell lung cancers (NSCLCs) with epidermal growth factor receptor (EGFR) mutations. However, relapse typically occurs after an average of 1 year of continuous ...
    • Reactivation of ERK Signaling Causes Resistance to EGFR Kinase Inhibitors 

      Ercan, Dalia; Xu, Chunxiao; Yanagita, Masahiko; Monast, Calixte S.; Pratilas, Christine A.; Montero, Joan; Butaney, Mohit; Shimamura, Takeshi; Sholl, Lynette Marie; Ivanova, Elena; Tadi, Madhavi; Rogers, Andrew; Repellin, Claire; Capelletti, Marzia; Maertens, Ophelia; Goetz, Eva Marie; Letai, Anthony George; Garraway, Levi Alexander; Lazzara, Matthew J.; Rosen, Neal; Gray, Nathanael Schiander; Wong, Kwok-Kin; Janne, Pasi Antero (American Association for Cancer Research (AACR), 2012)
      The clinical efficacy of EGFR kinase inhibitors is limited by the development of drug resistance. The irreversible EGFR kinase inhibitor WZ4002 is effective against the most common mechanism of drug resistance mediated by ...
    • ROS1 Immunohistochemistry for Detection of ROS1-Rearranged Lung Adenocarcinomas 

      Sholl, Lynette Marie; Sun, Heather; Butaney, Mohit; Zhang, Chengsheng; Lee, Charles; Janne, Pasi Antero; Rodig, Scott J. (Ovid Technologies (Wolters Kluwer Health), 2013)
      ROS1 gene rearrangements are reported in 1–2% of lung adenocarcinomas (ACA) and are associated with response to the multitargeted tyrosine kinase inhibitor, crizotinib. ROS1 rearrangements can be detected using fluorescence ...
    • Whole-exome sequencing and clinical interpretation of FFPE tumor samples to guide precision cancer medicine 

      Allen, Eliezer M. Van; Wagle, Nikhil; Stojanov, Petar; Perrin, Danielle L.; Cibulskis, Kristian; Marlow, Sara; Jane-Valbuena, Judit; Friedrich, Dennis C.; Kryukov, Gregory; Carter, Scott L.; McKenna, Aaron; Sivachenko, Andrey; Rosenberg, Mara; Kiezun, Adam; Voet, Douglas; Lawrence, Michael; Lichtenstein, Lee T.; Gentry, Jeff G.; Huang, Franklin W.; Fostel, Jennifer; Farlow, Deborah; Barbie, David; Gandhi, Leena; Lander, Eric S.; Gray, Stacy W.; Joffe, Steven; Janne, Pasi; Garber, Judy; MacConaill, Laura; Lindeman, Neal; Rollins, Barrett; Kantoff, Philip; Fisher, Sheila A.; Gabriel, Stacey; Getz, Gad; Garraway, Levi A. (2013)
      Translating whole exome sequencing (WES) for prospective clinical use may impact the care of cancer patients; however, multiple innovations are necessary for clinical implementation. These include: (1) rapid and robust WES ...